There were also reports in the literature that increased tumor-infiltrating lymphocyte (TIL) levels could predict pathological response in all BC subtypes and were associated with a survival benefit in the TNBC and HER2+ but not the luminal-HER2− subtype (41). This evidence concerns the gene ERBB2 and breast cancer.